Oncoinvent has reached the halfway enrollment point in its Phase 2 trial of Radspherin, an experimental alpha-radiation therapy for ovarian cancer patients with peritoneal metastases, as recruitment accelerates across multiple international clinical sites.
Radiopharmaceutical Therapy | 20/06/2026 | By News Bureau | 142
SK Biopharmaceuticals Expands Radiopharma Portfolio with New WARF In-Licensing
SK Biopharmaceuticals has in-licensed a second radiopharmaceutical therapy candidate from the Wisconsin Alumni Research Foundation (WARF), further strengthening its pipeline and advancing its strategy to build an integrated, globally competitive radiotherapeutics portfolio.
Radiopharmaceutical Therapy | 29/11/2025 | By Dineshwori | 285
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy